Migraine is one of the most common forms of headache. The cause is an increased release of inflammatory and vasodilator neurotransmitters, such as calcitonin gene-related peptide (CGRP). As a new therapeutic option, an antibody directed against the CGRP receptor has been developed, whose efficacy has been confirmed in clinical trials. A reduction in CGRP levels and an improvement in migraine symptoms could also be demonstrated by supplementation with the body’s own coenzyme Q10. However, coenzyme Q10, which is taken up in the form of powder capsules, is absorbed only to a small extent. By formulation with phospholipids, which occur naturally in the bile, the bioavailability can be significantly increased.